CD163 and non-small cell lung carcinoma: We also found that the response rate in NSCLC patients with a CD8+ high/CD8+PD-L1+ low or CD8+ high/CD68+CD163+ low signature was significantly higher than that in patients with the other corresponding signatures (Figure 5).